PharmEasy parent FY26 loss falls to Rs 520 crore
The move
API Holdings, the parent of PharmEasy, entered the quick commerce segment in FY26 while shifting towards higher-margin businesses including diagnostics, hospital management systems, pathology laboratories and generic pharmaceuticals. The company reduced its consolidated net loss by 67% to Rs 520 crore in the year ended March 2026, from Rs 1,572 crore in the previous fiscal year.
Revenue from operations rose 13% to Rs 6,619 crore, compared with Rs 5,872 crore in FY25.
What API Holdings does
API Holdings operates across pharmacy distribution and diagnostics, with products and services as its two income streams. Its businesses include Ascent Health and Wellness Solutions, which supplies pharmaceutical products to chemists and institutions, and AknaMed, which supplies hospitals with pharmaceutical products, consumables and surgical supplies.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
Through Thyrocare, the company provides diagnostic tests and services to consumers, hospitals and other B2B entities. PharmEasy is its consumer-facing operation and an e-commerce marketplace that facilitates the sale and purchase of pharmaceutical and over-the-counter products through third-party retail pharmacies and service providers. Diagnostics and other healthcare services are also cross-sold on the platform, which enables on-demand home delivery of prescription and over-the-counter pharmaceutical products.
Products and services
In FY26, API Holdings earned Rs 5,670 crore from products and Rs 941 crore from diagnostics, teleconsulting, licensing, fulfilment and technology services.
Its B2B businesses generated Rs 4,082 crore in FY26. PharmEasy reported Rs 1,335 crore in revenue and an EBITDA loss of Rs 44 crore.
More in Market Move
